Semaglutide is a long-acting GLP-1 peptide drug used to treat type 2 diabetes and obesity. It has a half-life of 7 days and can be administered as a weekly injection (Ozempic/Wegovy).
It lowers blood sugar, suppresses appetite, leads to 15% to 20% weight loss annually, and protects the heart. Common side effects include mild gastrointestinal discomfort.
Our products are provided in a freeze-dried, lyophilized powder that is vacuum sealed in a sterile vial format that typically require reconstitution with an applicable solvent or solution and intended for research use only.